- Home
- API vs RCKT Comparison
API vs RCKT Comparison
Compare API & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- API
- RCKT
- Stock Information
- Founded
- API 2013
- RCKT 1999
- Country
- API United States
- RCKT United States
- Employees
- API N/A
- RCKT N/A
- Industry
- API Computer Software: Prepackaged Software
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- API Technology
- RCKT Health Care
- Exchange
- API Nasdaq
- RCKT Nasdaq
- Market Cap
- API 343.2M
- RCKT 328.6M
- IPO Year
- API 2020
- RCKT N/A
- Fundamental
- Price
- API $3.45
- RCKT $3.28
- Analyst Decision
- API Strong Buy
- RCKT Buy
- Analyst Count
- API 1
- RCKT 13
- Target Price
- API $6.00
- RCKT $12.96
- AVG Volume (30 Days)
- API 508.9K
- RCKT 6.0M
- Earning Date
- API 08-18-2025
- RCKT 08-07-2025
- Dividend Yield
- API N/A
- RCKT N/A
- EPS Growth
- API N/A
- RCKT N/A
- EPS
- API N/A
- RCKT N/A
- Revenue
- API $133,554,000.00
- RCKT N/A
- Revenue This Year
- API $7.20
- RCKT N/A
- Revenue Next Year
- API $11.26
- RCKT $108.43
- P/E Ratio
- API N/A
- RCKT N/A
- Revenue Growth
- API N/A
- RCKT N/A
- 52 Week Low
- API $1.78
- RCKT $2.19
- 52 Week High
- API $6.99
- RCKT $22.01
- Technical
- Relative Strength Index (RSI)
- API 40.21
- RCKT 51.17
- Support Level
- API $3.48
- RCKT $2.88
- Resistance Level
- API $3.67
- RCKT $3.74
- Average True Range (ATR)
- API 0.19
- RCKT 0.27
- MACD
- API -0.02
- RCKT 0.02
- Stochastic Oscillator
- API 10.17
- RCKT 35.43
About API Agora Inc.
Agora Inc provides real-time communication solutions. The company offers real-time video calling, voice calling, live audio and video streaming, recording, and real-time messaging. It serves the gaming, retail, and education industries. The company operates in the People's Republic of China and the United States of America and the majority of its revenue is derived from the People's Republic of China.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.